Treffer 1 - 4 von 4 für Suche 'Van Etten, V.M.J.', Suchdauer: 0,33s Treffer weiter einschränken
  1. 1
    A0281 - GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer

    A0281 - GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer von Olislagers, M., De Jong, F.C., Van Etten, V.M.J., Kan, T.W., Zuiverloon, T.C.M.

    Veröffentlicht in European urology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer

    GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer von Olislagers, M., De Jong, F.C., Van Etten, V.M.J., Kan, T.W., Zuiverloon, T.C.M.

    Veröffentlicht in European urology

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    Validation of a GATA2 methylation and FGFR3 mutation assay to predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer

    Validation of a GATA2 methylation and FGFR3 mutation assay to predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer von Olislagers, M., De Jong, F.C., Van Etten, V.M.J., Kan, T.W., Zuiverloon, T.C.M.


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  4. 4
    Validation of a GATA2 methylation and FGFR3 mutation assay to predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer

    Validation of a GATA2 methylation and FGFR3 mutation assay to predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer von Olislagers, M., De Jong, F.C., Van Etten, V.M.J., Kan, T.W., Zuiverloon, T.C.M.


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: